Mirvetuximab Soravtansine 在叶酸受体α高表达铂耐药卵巢癌患者中的疗效与安全性:SORAYA 研究结果
SORAYA 是一项单臂 II 期研究,评估 Mirvetuximab Soravtansine(MIRV)在叶酸受体α高表达铂耐药上皮性卵巢癌(PROC)患者中的疗效与安全性。共入组 106 例,105 例可评估疗效;研究者确认的客观缓解率(ORR)为 32.4%(95%CI 23.6-42.2),中位缓解持续时间 6.9 个月(95%CI 5.6-9.7)。常见治疗相关不良事件包括视力模糊、角膜病变和恶心,整体耐受性良好。
要点
- MIRV 在 FRα 高表达 PROC 患者中研究者确认的 ORR 为 32.4%(95%CI 23.6-42.2)。
- 中位缓解持续时间为 6.9 个月(95%CI 5.6-9.7)。
- 常见治疗相关不良事件为视力模糊(41%)、角膜病变(29%)和恶心(29%)。
核心结论
- MIRV 在既往接受过最多三线治疗(包括贝伐珠单抗)的 FRα 高表达 PROC 患者中显示出一致的临床意义抗肿瘤活性及良好的耐受性和安全性,代表该生物标志物筛选人群的重要进展。
研究设计与样本
- SORAYA 是一项单臂 II 期研究,评估 MIRV 在铂耐药上皮性卵巢癌(PROC)患者中的疗效与安全性。
- 入组 FRα 高表达 PROC 患者,既往接受过一至三线治疗,且要求既往使用过贝伐珠单抗。
- 共入组 106 例患者,其中 105 例可评估疗效。
- 主要终点为研究者确认的客观缓解率(ORR),缓解持续时间是关键次要终点。
主要发现
- 所有患者均既往接受过贝伐珠单抗,51% 接受过三线既往治疗,48% 既往接受过聚 ADP 核糖聚合酶抑制剂。
- 中位随访时间为 13.4 个月。
- 研究者确认的 ORR 为 32.4%(95%CI 23.6-42.2),包括 5 例完全缓解和 29 例部分缓解。
- 中位缓解持续时间为 6.9 个月(95%CI 5.6-9.7)。
- 既往接受一至两线治疗的患者研究者确认的 ORR 为 35.3%(95%CI 22.4-49.9),既往接受三线治疗的患者为 30.2%(95%CI 18.3-44.3);既往接受过聚 ADP 核糖聚合酶抑制剂的患者 ORR 为 38.0%(95%CI 24.7-52.8),未接受过的患者为 27.5%(95%CI 15.9-41.7)。
关键数值与推荐
- 研究者确认的 ORR 为 32.4%(95%CI 23.6-42.2),包括 5 例完全缓解和 29 例部分缓解。
- 中位缓解持续时间为 6.9 个月(95%CI 5.6-9.7)。
- 最常见的治疗相关不良事件(所有级别和 3-4 级)为视力模糊(41% 和 6%)、角膜病变(29% 和 9%)和恶心(29% 和 0%)。
- 治疗相关不良事件导致剂量延迟、减量和停药的患者比例分别为 33%、20% 和 9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). SORAYA is a single-arm, phase II study evaluating efficacy and safety of MIRV in patients with PROC. METHODS: SORAYA enrolled FRα-high patients with PROC who had received one to three prior therapies, including required bevacizumab. The primary end point was confirmed objective response rate (ORR) by investigator; duration of response was the key secondary end point. RESULTS: One hundred six patients were enrolled; 105 were evaluable for efficacy. All patients had received prior bevacizumab, 51% had three prior lines of therapy, and 48% received a prior poly ADP-ribose polymerase inhibitor. Median follow-up was 13.4 months. ORR was 32.4% (95% CI, 23.6 to 42.2), including five complete and 29 partial responses. The median duration of response was 6.9 months (95% CI, 5.6 to 9.7). In patients with one to two priors, the ORR by investigator was 35.3% (95% CI, 22.4 to 49.9) and in patients with three priors was 30.2% (95% CI, 18.3 to 44.3). The ORR by investigator was 38.0% (95% CI, 24.7 to 52.8) in patients with prior poly ADP-ribose polymerase inhibitor exposure and 27.5% (95% CI, 15.9 to 41.7) in those without. The most common treatment-related adverse events (all grade and grade 3-4) were blurred vision (41% and 6%), keratopathy (29% and 9%), and nausea (29% and 0%). Treatment-related adverse events led to dose delays, reductions, and discontinuations in 33%, 20%, and 9% of patients, respectively. CONCLUSION: MIRV demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety in patients with FRα-high PROC who had received up to three prior therapies, including bevacizumab, representing an important advance for this biomarker-selected population.
引用
- Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023. PMID: 36716407. doi:10.1200/JCO.22.01900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。